24 results
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
9 May 24
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
4:17pm
mission to become a sustainable and growing oncology company improving outcomes for cancer patients.”
FIRST QUARTER 2024 FINANCIAL RESULTS
Net
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
13 Mar 24
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
4:16pm
to execute on our mission of extending the lives of cancer patients.”
FOURTH QUARTER and FULL YEAR 2023 FINANCIAL RESULTS
Net revenue was $91.5 million
8-K
EX-99.1
CHRS
Coherus BioSciences, Inc.
27 Oct 23
Regulation FD Disclosure
4:19pm
for the prevention and treatment of COVID-19.
With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs”, Junshi
8-K
EX-99.1
jq8l0t4a59i sk
8 Nov 21
Coherus BioSciences Reports Third Quarter 2021 Results
4:06pm
8-K
EX-99.1
9w20ue
13 Oct 21
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
gx3ac 54d4ijg1t6x5
29 Sep 21
Departure of Directors or Certain Officers
5:07pm
8-K
EX-99.1
i4govf308072tu478bp8
5 Aug 21
Coherus BioSciences Reports Second Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:06pm
8-K
EX-99.1
bhwncwtfrnray3k2
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
8-K
EX-99.1
yxygn4wi 88za
24 Feb 21
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
4:05pm
8-K
EX-99.2
xugb0ms8fv
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
8-K
EX-99.1
aetkx4cni
2 Feb 21
Entry into a Material Definitive Agreement
8:45am